Pharmacology · patient case question
Apart from bisphosphonates, which drug class is most associated with medication-related osteonecrosis of the jaw?
Patient case: Bisphosphonates and a Diastema
Patient: 67-year-old female
Chief Complaint: “I've always hated the gap between my front teeth. Can it be closed?”
Background: Osteoporosis, on oral alendronate for four years. Tooth #8 was root treated eight years ago.
Medications: Alendronate 70 mg weekly, calcium, vitamin D
Vital Signs: BP 134/78 mmHg · HR 70 bpm · RR 16 · T 98.4°F
Findings: A 2.5 mm midline diastema between #8 and #9. Tooth #8 is root treated with an intact but discoloured crown; #9 is vital and unrestored. Periodontium is healthy with no bone loss.
Show answer and explanation
Correct answer: C. Antiangiogenic agents
- A. Antihypertensives have no association with osteonecrosis of the jaw.
- B. Antibiotics are part of MRONJ MANAGEMENT, not its cause.
- C. CORRECT. ANTIANGIOGENIC agents are the other major MRONJ class. Bevacizumab (a VEGF monoclonal antibody) and the tyrosine kinase inhibitors sunitinib and sorafenib block new vessel formation, and bone that cannot revascularise cannot heal after injury. Denosumab, a RANKL inhibitor, is the third major agent — antiresorptive like the bisphosphonates but through a different mechanism.
- D. Antihistamines have no association with MRONJ.
Note: Full MRONJ drug list worth knowing: nitrogen-containing bisphosphonates (alendronate, zoledronate, pamidronate), denosumab, and the antiangiogenics (bevacizumab, sunitinib, sorafenib). Risk rises steeply with IV oncology dosing, duration over four years, corticosteroid co-therapy, diabetes and smoking.